Cytori Therapeutics, Inc. (CYTX) SEC Filing 8-K Material Event for the period ending Thursday, June 27, 2019

Cytori Therapeutics, Inc.

CIK: 1095981 Ticker: CYTX

View differences made from one to another to evaluate Cytori Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Cytori Therapeutics, Inc..


Assess how Cytori Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Cytori Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Cytori Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: CYTX
CIK: 1095981
Form Type: 8-K Corporate News
Accession Number: 0001564590-19-023871
Submitted to the SEC: Thu Jun 27 2019 5:20:29 PM EST
Accepted by the SEC: Thu Jun 27 2019
Period: Thursday, June 27, 2019
Industry: Surgical And Medical Instruments And Apparatus
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: